| Genome-wide association study identifies five new schizophrenia loci Nature genetics 43 (10), 969-976, 2011 | 2020 | 2011 |
| Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis V Simon, P Czobor, S Bálint, A Mészáros, I Bitter The British Journal of Psychiatry 194 (3), 204-211, 2009 | 2009 | 2009 |
| Common variants conferring risk of schizophrenia H Stefansson, RA Ophoff, S Steinberg, OA Andreassen, S Cichon, ... Nature 460 (7256), 744-747, 2009 | 1947 | 2009 |
| Updated European Consensus Statement on diagnosis and treatment of adult ADHD JJS Kooij, D Bijlenga, L Salerno, R Jaeschke, I Bitter, J Balazs, J Thome, ... European psychiatry 56 (1), 14-34, 2019 | 636 | 2019 |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and … M Bauer, A Pfennig, E Severus, PC Whybrow, J Angst, HJ Möller, ... The world journal of biological psychiatry 14 (5), 334-385, 2013 | 612 | 2013 |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of … M Bauer, PC Whybrow, J Angst, M Versiani, HJ Möller, ... The World Journal of Biological Psychiatry 3 (1), 5-43, 2002 | 530 | 2002 |
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of … H Grunze, E Vieta, GM Goodwin, C Bowden, RW Licht, HJ Möller, ... The World Journal of Biological Psychiatry 14 (3), 154-219, 2013 | 502 | 2013 |
| Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial EJ Daly, MH Trivedi, A Janik, H Li, Y Zhang, X Li, R Lane, P Lim, AR Duca, ... JAMA psychiatry 76 (9), 893-903, 2019 | 493 | 2019 |
| Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial MJ Detke, CG Wiltse, CH Mallinckrodt, RK McNamara, MA Demitrack, ... European Neuropsychopharmacology 14 (6), 457-470, 2004 | 400 | 2004 |
| Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial G Németh, I Laszlovszky, P Czobor, E Szalai, B Szatmári, J Harsányi, ... The Lancet 389 (10074), 1103-1113, 2017 | 393 | 2017 |
| Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors CU Correll, M Solmi, G Croatto, LK Schneider, SC Rohani‐Montez, ... World Psychiatry 21 (2), 248-271, 2022 | 296 | 2022 |
| Stratified medicine for mental disorders G Schumann, EB Binder, A Holte, ER de Kloet, KJ Oedegaard, ... European Neuropsychopharmacology 24 (1), 5-50, 2014 | 278 | 2014 |
| Common variants at VRK2 and TCF4 conferring risk of schizophrenia S Steinberg, S de Jong, OA Andreassen, T Werge, AD Børglum, O Mors, ... Human molecular genetics 20 (20), 4076-4081, 2011 | 251 | 2011 |
| Attention deficit hyperactivity disorder (ADHD): gender-and age-related differences in neurocognition S Bálint, P Czobor, S Komlósi, A Meszaros, V Simon, I Bitter Psychological medicine 39 (8), 1337-1345, 2009 | 233 | 2009 |
| Mental health research priorities for Europe T Wykes, JM Haro, SR Belli, C Obradors-Tarragó, C Arango, ... The Lancet Psychiatry 2 (11), 1036-1042, 2015 | 219 | 2015 |
| Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial S Galderisi, A Mucci, I Bitter, J Libiger, P Bucci, WW Fleischhacker, ... European Neuropsychopharmacology 23 (3), 196-204, 2013 | 218 | 2013 |
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment H Grunze, S Kasper, G Goodwin, C Bowden, H Mo¨ ller, ... The World Journal of Biological Psychiatry 5 (3), 120-135, 2004 | 199 | 2004 |
| Genetic Risk and Outcome in Psychosis (GROUP). Common variants conferring risk of schizophrenia H Stefansson, RA Ophoff, S Steinberg, OA Andreassen, S Cichon, ... Nature 460 (7256), 744-747, 2009 | 198 | 2009 |
| Expanding the range of ZNF804A variants conferring risk of psychosis S Steinberg, O Mors, AD Børglum, O Gustafsson, T Werge, PB Mortensen, ... Molecular psychiatry 16 (1), 59-66, 2011 | 182 | 2011 |
| EPA guidance on assessment of negative symptoms in schizophrenia S Galderisi, A Mucci, S Dollfus, M Nordentoft, P Falkai, S Kaiser, ... European Psychiatry 64 (1), e23, 2021 | 181 | 2021 |